Previous 10 | Next 10 |
Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against financial objectives Planned merger with SomaLogic activates strategic M&A thesis SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bio...
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give...
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday,...
2023-10-04 18:49:14 ET An upcoming merger involving SomaLogic (NASDAQ: SLGC) wasn't making investors happy on Wednesday. On its news that it would be combining with medical technology peer Standard BioTools (NASDAQ: FLDM) , investors traded out of the shares. Ultimately, Som...
Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach ...
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) (“Standard BioTools”, or the “Company”), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported f...
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday...
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced Company management will participate in the following investor confe...
SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will ...
SOUTH SAN FRANCISCO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of NGS library preparation functionality on the X9™ Hi...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...